What are the treatment options for pan‑resistant Candida infection?

Management of Pan-Resistant Candida Infection

For pan-resistant Candida infections, lipid formulation amphotericin B (3-5 mg/kg daily) is the primary treatment option, with combination antifungal therapy warranted in severe cases despite limited clinical trial data supporting this approach.

Primary Treatment Strategy

First-Line Therapy

• Lipid formulation amphotericin B (LAmB) at 3-5 mg/kg daily is the recommended agent when resistance to azoles and echinocandins is documented or suspected 1
• This recommendation is based on strong evidence for use in resistant infections, though the quality of evidence is low 1
• LAmB should be preferred over amphotericin B deoxycholate due to better tolerability, though both retain activity against most resistant strains

Combination Therapy Considerations

When dealing with truly pan-resistant organisms (resistant to azoles, echinocandins, amphotericin B, and flucytosine):

• Consider combination therapy with LAmB plus flucytosine (25 mg/kg four times daily) 1
• This approach is supported for salvage therapy in patients not responding to initial treatment 1
• Important caveat: Pan-resistant C. auris isolates have shown no susceptibility to two-drug combinations in vitro testing, including checkerboard, Etest, and time-kill methods 2
• Despite lack of synergy data, combination therapy may be justified in life-threatening infections to maximize antifungal pressure

Critical Adjunctive Measures

Source Control (Mandatory)

• Remove all central venous catheters within 48-72 hours if safely possible 1, 3
• This is a strong recommendation with moderate-quality evidence and is non-negotiable for candidemia 1
• For intra-abdominal candidiasis, surgical drainage and debridement are essential 1
• Remove or replace infected CNS devices, nephrostomy tubes, or other prosthetic materials 1

Monitoring Requirements

• Daily blood cultures until three consecutive negative results 3
• If cultures remain positive at day 5, repeat search for uncontrolled sources 3
• Dilated ophthalmologic examination within the first week for all candidemia patients 1
• Imaging (CT or ultrasound) of liver, spleen, and genitourinary tract if blood cultures persistently positive 1

Species-Specific Considerations

For Pan-Resistant C. auris

This represents the most concerning scenario, as documented cases show resistance to all four major antifungal classes 2:

• High-dose LAmB (5 mg/kg daily) remains the best option
• Combination therapy with LAmB plus an echinocandin or flucytosine should be attempted despite in vitro evidence suggesting lack of synergy 2
• Novel agents (rezafungin, ibrexafungerp, fosmanogepix) may be considered through compassionate use or clinical trials 4
• Resistance mechanisms include ERG11 mutations (azole resistance), FKS1 mutations (echinocandin resistance), and FUR1 deletions (flucytosine resistance) 2

For Multidrug-Resistant C. glabrata

• If only azole and echinocandin resistant but amphotericin-susceptible:
  • LAmB 3-5 mg/kg daily 1
  • Consider adding flucytosine if susceptible 1
• DNA mismatch repair gene mutations in C. glabrata facilitate acquisition of resistance, making this species particularly prone to developing pan-resistance 5

Site-Specific Management

CNS Infections

• LAmB 5 mg/kg daily combined with flucytosine is strongly recommended 3
• Amphotericin B deoxycholate is only moderately recommended and should not be used if LAmB is available 3
• Continue therapy until all signs, symptoms, CSF abnormalities, and radiological findings resolve 1

Endocarditis

• LAmB 3-5 mg/kg daily with or without flucytosine OR high-dose echinocandin (if any susceptibility remains) 1
• Valve replacement is mandatory 1
• Treat for at least 6 weeks post-surgery 1

Ocular Candidiasis

• Avoid echinocandins due to poor penetration into posterior chamber 3
• Use LAmB systemically, particularly for resistant organisms 3
• Intravitreal antifungal therapy or vitrectomy may be needed for endophthalmitis 3

Duration of Therapy

• Minimum 2 weeks after documented bloodstream clearance and resolution of symptoms for uncomplicated candidemia 1
• Longer duration required for:
  • Persistent positive cultures beyond 5 days
  • Metastatic complications
  • Endocarditis (≥6 weeks post-surgery)
  • CNS involvement (until complete resolution)

Common Pitfalls to Avoid

1. Do not rely on echinocandins even at high doses (caspofungin 150 mg, micafungin 150 mg, anidulafungin 200 mg daily) if FKS1 mutations are documented 1

2. Do not use fluconazole or voriconazole for pan-resistant organisms, even as step-down therapy 1

3. Do not delay source control while waiting for susceptibility results—remove catheters and drain abscesses immediately 1, 3

4. Do not assume combination therapy will be synergistic—recent data on pan-resistant C. auris shows no benefit from combinations in vitro 2

5. Do not use standard amphotericin B doses—resistant infections may require higher doses (5 mg/kg for LAmB) 3

Emerging Therapeutic Options

While not yet widely available, consider these for compassionate use in truly pan-resistant cases:

• Rezafungin (FDA-approved March 2023 for candidemia/invasive candidiasis) 4
• Ibrexafungerp (phase III trials completed) 4
• Fosmanogepix (phase III trials ongoing) 4

Key Clinical Context

The emergence of pan-drug resistance is alarming and represents an urgent antimicrobial resistance threat 2. Patients at highest risk include those undergoing multi-visceral transplantation, those with prolonged ICU stays, and those with prior extensive antifungal exposure 2, 5. Targeted pre- and post-transplant surveillance may be warranted for high-risk patients 2. The mortality rate for invasive candidiasis remains approximately 44% within 30 days, emphasizing the critical importance of aggressive early management 6.